Please login to the form below

Not currently logged in


This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

Bayer's lymphoma drug copanlisib gets speedy FDA review

Bayer's lymphoma drug copanlisib gets speedy FDA review

Bayer is in pursuit of Gilead Sciences' P13K inhibitor Zydelig (idelalisib), which is already approved for FL and chronic lymphocytic leukaemia (CLL) in the US but hasn't lived up to ... It's worth noting that idelalisib targets a single P13K isoform

Latest news

More from news
Approximately 4 fully matching, plus 27 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Conversis Medical

Conversis Medical is a translation company specialising in translation and localisation for the medical industry, particularly in clinical trial projects....

Latest intelligence

Rare diseases: meeting the challenge
Problems with regulating orphan drugs...
Digital storytelling means building the story around data
The value of digital storytelling in pharma lies in its ability to convert facts and figures into compelling content for patients and HCPs....
Pharma and free medicines: a different perspective
Pfizer have recently announced that they will provide the breast cancer drug, palbociclib, free of charge to patients....